Latest Diagnostics News

Page 37 of 40
Pro Medicus has inked a $53 million, seven-year contract with BayCare to deploy its Visage 7 cloud-based imaging platform across Florida’s largest healthcare system, marking a major step in its North American expansion.
Ada Torres
Ada Torres
4 Feb 2025
Rhythm Biosciences has fast-tracked the integration of the geneType™ business, restoring full commercial capabilities ahead of schedule and setting the stage for expanded market reach.
Ada Torres
Ada Torres
4 Feb 2025
Beamtree Holdings appoints Marek Stepniak as CEO, signaling a strategic push in international markets with a strong leadership hand familiar with the company’s growth trajectory.
Ada Torres
Ada Torres
4 Feb 2025
Optiscan Imaging has initiated a pivotal pre-clinical gastrointestinal study in Germany using its first flexible prototype, aiming to revolutionize real-time GI tract imaging and diagnostics.
Ada Torres
Ada Torres
3 Feb 2025
Rewardle Holdings reports a strong December quarter with positive cash flow and a significant valuation uplift in its CloudHolter partnership, underpinning its multi-pronged growth strategy.
Sophie Babbage
Sophie Babbage
31 Jan 2025
Cleo Diagnostics reports steady progress in its U.S. and Australian clinical trials for an ovarian cancer blood test, maintaining a solid cash reserve of A$7.3 million as it prepares for FDA submission.
Ada Torres
Ada Torres
31 Jan 2025
Clarity Pharmaceuticals reports robust progress in its SECURE trial and secures FDA Fast Track Designation for its diagnostic agent 64Cu-SAR-bisPSMA, underpinning its growth and innovation in prostate cancer treatment.
Victor Sage
Victor Sage
31 Jan 2025
BCAL Diagnostics is poised to launch its innovative BREASTEST® breast cancer diagnostic test in early 2025, backed by recent NATA accreditation, patent acceptance, and a $2.6 million R&D tax offset.
Ada Torres
Ada Torres
31 Jan 2025
IMEXHS Limited reported a robust 34% increase in FY24 revenue to $26.5 million, driven by new contracts in Colombia and Peru that boosted its Annual Recurring Revenue to $30 million. Despite a slight EBITDA shortfall due to a bad debt expense, the company highlighted operational improvements and strengthened its regional footprint.
Ada Torres
Ada Torres
31 Jan 2025
Genetic Signatures reported a robust 190% increase in quarterly sales to $3.8 million, driven by strong respiratory testing demand in Australia and strategic UK deployments. Despite longer US sales cycles, the company maintains a solid $40.8 million cash position and advances R&D on its 3base® platform.
Ada Torres
Ada Torres
31 Jan 2025
INOVIQ's December quarterly update reveals significant progress in its cancer diagnostic and therapeutic programs, including a highly accurate ovarian cancer screening test and promising breast cancer therapeutics, supported by growing EXO-NET customer adoption and a solid cash position.
Ada Torres
Ada Torres
31 Jan 2025
Lumos Diagnostics reported a robust Q2 FY25 with a 71% revenue increase to US$2.9 million, driven by strong product and service sales, alongside a strategic US$3 million BARDA partnership to advance its FebriDx test.
Ada Torres
Ada Torres
31 Jan 2025